Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats

Reference

• ALLONEN, H., ZIEGLER, G. and KLOTZ, U., 1981, Midazolam kinetics. Clinical Pharmacology and Therapeutics, 30, 653–661.
   PubMed Web of Science ®Google Scholar
• CARRILLO, J. A., RAMOS, S. I., AGUNDEZ, J. A. G., MARTINEZ, C. and BENITEZ, J., 1998, Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Therapeutic Drug Monitoring, 20, 319–324.
   Google Scholar
• CORCOS, L., 1992, Phenobarbital and dexamethasone induce expression of cytochrome P-450 genes from subfamilies JIB, IIC, and IIIA in mouse liver. Drug Metabolism and Disposition, 20, 797–801.
   PubMed Web of Science ®Google Scholar
• DELAFORGE, M., JAOUEN, M. and MANSUY, D., 1983, Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship. Biochemical Pharmacology, 32, 2309–2318.
   PubMed Web of Science ®Google Scholar
• GASCON, M. P. and DAYER, P., 1991, In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. European Journal of Clinical Pharmacology, 41, 573–578.
   PubMed Web of Science ®Google Scholar
• GHOSAL, A., SADRIEH, A., REIK, L., LEVIN, W. and THOMAS, P. E., 1996b, Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Archives of Biochemistry and Biophysics, 332, 153–162.
   PubMed Web of Science ®Google Scholar
• GHOSAL, A., SATO, H., THOMAS, P. E., BUSH, E. and MOORE, D., 1996a, Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940–947.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1999, Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1–17.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., DANNAN, G. A., WRIGHT, S. T., MARTIN, M. V. and KAMINSKY, L. S., 1982, Purification and characterization of liver microsomal cytochromes P-450: Electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or 13-naphtofiavone. Biochemistry, 21, 6019–6030.
   PubMed Web of Science ®Google Scholar
• IMAOKA, S., FUJITA, S. and FUNAE, Y., 1991, Age-dependent expression of cytochrome P-450s in rat liver. Biochimica et Biophysica Acta, 1097, 187–192.
   PubMed Web of Science ®Google Scholar
• IMAOKA, S., TERANO, Y. and FUNAE, Y., 1988, Constitutive testosterone 613-hydroxylase in rat liver. Journal of Biochemistry (Tokyo), 104, 481–487.
   PubMed Web of Science ®Google Scholar
• ISHIGAMI, M., KAWABATA, K., TAKASAKI, W., IKEDA, T., KOMAI, T., ITo, K. and SUGIYAMA, Y., 2001, Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metabolism and Disposition, 29, 1068–1072.
   PubMed Web of Science ®Google Scholar
• ITo, K., IWATSUBO, T., KANAMITSU, S., UEDA, K., SUZUKI, H. and SUGIYAMA, Y., 1998, Prediction of pharmacokinetic alterations caused by drug—drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387–411.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., 00IE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T. GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   Google Scholar
• JONES, D. R., GORSKI, J. C., HAMMAN, M. A., MAYHEW, B. S., RIDER, S. and HALL, S., 1999, Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. Journal of Pharmacology and Experimental Therapeutics, 290, 1116–1125.
   PubMed Web of Science ®Google Scholar
• KANAZU, T., YAMAGUCHI, Y OKAMURA, N., BABA, T. and KOIKE, M., 2004, Model for the drug—drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica, 34, 391–402.
   Google Scholar
• KIRITA, S. and MATSUBARA, T., 1993, cDNA cloning and characterization of a novel member of steroid-induced cytochrome P450 3A in rats. Archives of Biochemistry and Biophysics, 307, 253–258.
   PubMed Web of Science ®Google Scholar
• KUPERMAN, A. V., KALGUTKAR, A. S., MARFAT, A., CHAMBERS, R. and LISTON, T., 2001, Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro—in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metabolism and Disposition, 29, 1403–1409.
   PubMed Web of Science ®Google Scholar
• MA, B., PRUEKSARITANONT, T. and LIN, J. H., 2000, Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metabolism and Disposition, 28, 125–130.
   PubMed Web of Science ®Google Scholar
• MAHNKEA, A., ROOSA, P. H., HANSTEINA, W. G. and CHABOTA, G. G., 1996, In vitro induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. Biochemical Pharmacology, 51, 1579–1582.
   PubMed Web of Science ®Google Scholar
• MATSUBARA, T., OTSUBO, S. and YOSHIHARA, E., 1983, Liver microsomal cytochrome P-450-dependent 0-dealkylation reaction in various animals. Japanese Journal of Pharmacology, 33, 1065–1075.
   PubMedGoogle Scholar
• NAKAMURA, A., HIROTA, T., MORINO, A., IMAOKA, S., FUNAE, Y., YAMAMOTO, Y., TASAKI, T., MASUDA, M., KAZUSAKA, A. and FUJITA, S., 1999, Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21. Xenobiotica, 29, 243–252.
   PubMed Web of Science ®Google Scholar
• OLKKOLA, K. T., ARANKO, K., LUURILA, H., HILLER, A., SAARNIVAARA, L., HIMBERG, J. J. and NEUNONEN, P. J., 1993, A Potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298–305.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT, T., GORHAM, L. M., MA, B., Liu, L., Yu, X., ZHAO, J. J., SLAUGHTER, D. E., ARISON, B. H. and VYAS, K. P., 1997, In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition, 25, 1191–1199.
   PubMed Web of Science ®Google Scholar
• SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem. Journal of Pharmacology and Experimental Therapeutics, 282, 294–300.
   PubMed Web of Science ®Google Scholar
• TAKEDOMI, S., MATSUO, H., YAMANO, K., OHTANI, H. and SAWADA, Y., 2000, In-vivo kinetics of the interaction between midazolam and erythromycin in rats. Taking account of metabolic intermediate complex formation. Journal of Pharmacy and Pharmacology, 53, 643–651.
   Web of Science ®Google Scholar
• THUMMEL, K. E. and WILKINSON, G. R., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology, 38, 389–430.
   PubMed Web of Science ®Google Scholar
• TRIEU, L. and MURRAY, M., 2000, Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem. Xenobiotica, 30, 131–141.
   PubMed Web of Science ®Google Scholar
• VICKERS, S., DUNCAN, C. A., VYAS, K. P., KARI, P. H., ARISON, B., PRAKASH, S. R., RAMJIT, H. G., PITZENBERGER, S. M., STOKKER, G. and DUGGAN, D. E., 1990, In vitro and in vivo biotransformation of simvastatin, and inhibitor of HMG-CoA reductase. Drug Metabolism and Disposition, 18, 476–483.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., WRIGHT, C. E., HARMATZ, J. S. and SHADER, R. I., 1998, In vitro approaches to predicting drug interactions in vivo. Biochemical Pharmacology, 55, 113–122.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed l'-hydroxyl midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceutical Research, 11, 921–924.
   PubMed Web of Science ®Google Scholar